180 related articles for article (PubMed ID: 31883432)
1. Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis.
Herold Z; Herold M; Nagy P; Patocs A; Doleschall M; Somogyi A
J Diabetes Investig; 2020 Jul; 11(4):865-873. PubMed ID: 31883432
[TBL] [Abstract][Full Text] [Related]
2. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis.
Kalkan Ç; Karakaya F; Soykan İ
Turk J Gastroenterol; 2016 Nov; 27(6):515-520. PubMed ID: 27852542
[TBL] [Abstract][Full Text] [Related]
4. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.
Peracchi M; Gebbia C; Basilisco G; Quatrini M; Tarantino C; Vescarelli C; Massironi S; Conte D
Eur J Endocrinol; 2005 Mar; 152(3):443-8. PubMed ID: 15757862
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin Serves as Novel Biomarker of Endocrine and Gastric Autoimmunity.
Ebert A; König J; Frommer L; Schuppan D; Kahaly GJ
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32436949
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of gastrin levels for the diagnosis of gastric enterochromaffin-like cell hyperplasia in patients with Hashimoto's thyroiditis.
Nicolaou A; Thomas D; Alexandraki KI; Sougioultzis S; Tsolakis AV; Kaltsas G
Neuroendocrinology; 2014; 99(2):118-22. PubMed ID: 24776735
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
[TBL] [Abstract][Full Text] [Related]
8. Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?
Alexandraki KI; Nikolaou A; Thomas D; Syriou V; Korkolopoulou P; Sougioultzis S; Kaltsas G
Clin Endocrinol (Oxf); 2014 May; 80(5):685-90. PubMed ID: 24118101
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A as a useful neuroendocrine marker in patients with autoimmune Addison's disease.
El Ali Z; Fichna M; Piniewska J; Kosowicz J; Grzymisławski M
J Endocrinol Invest; 2010 Mar; 33(3):186-91. PubMed ID: 19794299
[TBL] [Abstract][Full Text] [Related]
10. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
11. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
13. The gastric mucosa 25 years after proximal gastric vagotomy.
Sagatun L; Jianu CS; Fossmark R; Mårvik R; Nordrum IS; Waldum HL
Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.
Tartaglia A; Portela-Gomes GM; Oberg K; Vezzadini P; Foschini MP; Stridsberg M
Virchows Arch; 2006 Apr; 448(4):399-406. PubMed ID: 16408221
[TBL] [Abstract][Full Text] [Related]
15. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
16. [Study on histogenesis of enterochromaffin-like carcinoid in autoimmune atrophic gastritis associated with pernicious anemia].
Macukanović-Golubović L; Katić V; Rancić G; Milenović M; Marjanović G; Golubović Z
Vojnosanit Pregl; 2007 Aug; 64(8):543-8. PubMed ID: 17874722
[TBL] [Abstract][Full Text] [Related]
17. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
19. Plasma ghrelin concentrations in type 1 diabetic patients with autoimmune atrophic gastritis.
Alonso N; Granada ML; Salinas I; Reverter JL; Flores L; Ojanguren I; Martínez-Cáceres EM; Sanmartí A
Eur J Endocrinol; 2007 Dec; 157(6):763-9. PubMed ID: 18057384
[TBL] [Abstract][Full Text] [Related]
20. Polyautoimmunity in autoimmune gastritis.
Kalkan Ç; Soykan I
Eur J Intern Med; 2016 Jun; 31():79-83. PubMed ID: 27085391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
